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Background: Reactive oxygen species (ROS), such as hydrogen peroxide and superoxide,
trigger biodegradation of polymer-based nanoparticles (NPs) bearing pinacol-type boronic
ester groups. These NPs may selectively release their cargo, in this case paclitaxel (PTX), at
the high levels of ROS present in the intracellular environment of inflamed tissues and most
tumors.
Purpose: The main objective was to determine anti-tumor efficacy of PTX-loaded ROS-
sensitive NPs and to examine whether macrophage infiltration had any impact on treatment
efficacy.
Methods: NPs were synthesized and their characteristics in the presence of H2O2 were
demonstrated. Both confocal microscopy as well as flow cytometry approaches were used to
determine degradation of ROS-sensitive NPs. HeLa cells were cultured in vitro and used to
establish tumor xenografts in nude mice. In vivo experiments were performed to understand
toxicity, biodistribution and anti-tumor efficacy of the NPs. Moreover, we performed immu-
nohistochemistry on tumor sections to study infiltration of M1 and M2 subsets of
macrophages.
Results: We demonstrated that PTX delivered in NPs containing a ROS-sensitive polymer
exhibits a better anti-tumor efficacy than PTX in NPs containing ROS-non-sensitive poly-
mer, free PTX or Abraxane® (nab-PTX). The biodistribution revealed that ROS-sensitive
NPs exhibit retention in liver, spleen and lungs, suggesting a potential to target cancer
metastasizing to these organs. Finally, we demonstrated a correlation between infiltrated
macrophage subsets and treatment efficacy, possibly contributing to the efficient anti-tumor
effects.
Conclusion: Treatment with ROS-sensitive NPs containing PTX gave an improved ther-
apeutic effect in HeLa xenografts than their counterpart, free PTX or nab-PTX. Our data
revealed a correlation between macrophage infiltration and efficiency of the different anti-
tumor treatments, as the most effective NPs resulted in the highest infiltration of the anti-
tumorigenic M1 macrophages.
Keywords: reactive oxygen species, ROS-sensitive nanoparticles, paclitaxel, treatment
efficacy, macrophage infiltration
Introduction
Reactive oxygen species (ROS) are necessary for growth and development of
living organisms1 and involved in biological processes, such as antimicrobial
defense and radiation damage.2 ROS are considered as being mainly formed as
by-products of mitochondrial respiration. Cells can protect themselves against
ROS damage by the use of specific ROS-reducing machineries that can either
be non-enzymatic (eg, glutathione, α-tocopherol and ascorbate) or enzymatic
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(catalase, superoxide dismutase, peroxidases and
reductases).3 Consequently, progressive reduction in
such intracellular ROS scavenging leads to increased
intracellular oxidative stress (Figure 1).4
Increased levels of ROS in cells initiate several forms
of reversible or irreversible oxidative modifications of
DNA, lipids and proteins, which may cause a loss of
molecular functions.5 ROS play an important role in an
extensive range of conditions, eg, chronic inflammation,
aging, diabetes, cardiovascular diseases and obesity.6–10
ROS have also been shown to be involved in various
cancer types, for instance, breast, cervical, ovarian, pan-
creatic, lung, liver, lymphoma and brain,11–18 either by
introducing gene mutations, decreasing apoptosis or
increasing cell proliferation and thereby adding further
DNA alterations.19
Advanced drug delivery systems aim at delivering larger
amounts of a therapeutic agent in the tumor while limiting its
systemic exposure, thus reducing systemic toxicity and
improving the selectivity of the treatment.20,21
Nanoparticles (NPs) containing encapsulated drugs and
allowing slow release of the drug in the tumor vicinity have
been developed to reach this goal.22,23 The NPs may have
incorporated motives that are sensitive to external stimuli,
thereby inducing degradation and drug release. Such external
stimuli could be a change in pH, enzymatic removal of
protecting groups, light or the presence of ROS.24 Pinacol-
type boronic ester groups are the most sensitive and selective
probes reported to detect H2O2 at physiological
concentrations.25,26 Based on this, novel biocompatible and
biodegradable ROS-sensitive polymers containing boronic
ester groups have been developed; these substances self-
degrade in ROS-rich areas and thereby release their drug
cargo.27–29
Although it is difficult to quantify the exact ROS con-
centration in various tissues including tumor, it is widely
accepted that highly proliferative cancer cells produce
elevated amounts of ROS compared to healthy cells.30
The overall effects of ROS on tumors range from tumor-
promoting to tumor-destroying effects, which means that
excess ROS production is potentially dangerous for both
the tumor and the host.31 Previously, we demonstrated in
vitro degradation of paclitaxel (PTX)-loaded ROS-sensi-
tive NPs in the presence of H2O2, and enhanced toxicity in
various cancer cell lines was achieved when compared to
the ROS-non-sensitive counterpart.29
The present study was undertaken to investigate the toxi-
city, biodistribution and treatment efficacy of PTX-loaded
ROS-sensitive NPs, in vivo. The toxicity of the NPs and free
PTX was tested on healthy mice. Treatment efficacy was
investigated utilizing subcutaneously growing HeLa xeno-
grafts, while treatment-induced leukocyte infiltration, focus-
ing on tumor-associated macrophages (TAM) and natural
killer (NK) cells, was assessed by immunohistochemistry.
The NPs were well tolerated and the ROS-sensitive NPs
showed improved anti-tumor efficacy compared to free
PTX and to Abraxane® (nab-PTX), a commercially available
albumin-bound PTX formulation. Increased pro-inflamma-
tory/anti-tumorigenicM1 macrophage infiltration and
reduced anti-inflammatory/pro-tumorigenic M2 macrophage
infiltration were observed in the tumors treated with the
ROS-sensitive NPs compared to all other treatments,
















Figure 1 Overview of general promoters and reducers of reactive oxygen species (ROS). ROS are products of cellular respiration and their formation can contribute to
oxidative stress and conditions, such as carcinogenesis, inflammation and aging. Upon elevated levels of ROS, cells may protect themselves by activating ROS reducing
enzymatic or non-enzymatic mechanisms. Some factors that contribute to increasing or decreasing the ROS level are listed in the figure.
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Abraxane® (nab-PTX- NPs containing albumin-bound PTX)
was purchased from Celgene (Uxbridge, UK) and PTX was
purchased from Mylan (Saint-Priest, France) for treatment
efficacy study using free PTX. Triethylamine (≥99.5%),
copper (I) iodide (99.999%), Nile Red (NR) for microscopy,
BSA and bovine liver catalase were all obtained from Sigma-
Aldrich (Prague, Czech Republic) and were used without
further purification. AlexaFluor® 647 was purchased from
Life Technologies (Carlsbad, CA, USA). For NP encapsula-
tion, PTX was purchased from Aurisco (Yangzhou, People’s
Republic of China). Polymethylmethacrylate (PMMA) stan-
dards were purchased from Polymer Source (Canada). All
solvents, unless otherwise stated, were used without further
purification.
Polymer synthesis and characterization
The ROS-sensitive polymer P1 and the ROS-non-sensitive
counterpart polymer P2 were synthesized and fully char-
acterized according to our previous work.29
Synthesis of the polymers with conjugated alexafluor
647
The charged polymer P1 or P2 (40 mg, 0.05 mmol terminal
alkyne groups), AlexaFluor 647 azide dye (0.5 mg, 0.59
µmol) and triethylamine (10 μL, 0.05 mmol) were added to
a vial containing 2.5 mL anhydrous N,N-dimethylforma-
mide (DMF; Sigma-Aldrich, Czech Republic) and equipped
with a magnetic stirrer (used under argon atmosphere) cop-
per (I) iodide (0.2 mg, 1 µmol) was added, followed by
stirring at room temperature for 5 mins, and thereafter
stirred vigorously for 6 hrs at 40°C. After cooling of the
reaction mixture, the copper catalyst was removed by filter-
ing and finally dialyzed for 48 hrs in the dark. The P1 and P2
polymer-AlexaFluor 647 conjugates were recovered by
lyophilization as light blue solids (Figure S1).
NP preparation
Solutions of P1 or P2 in acetone (5 mL, 10 mg·mL−1),
were added 250 μg·mL−1 of PTX and PBS (10.0 mL,
containing 0.01% (v/v) Tween 80). The NPs were then
formed following aggregation of the polymers due to the
increased solvent polarity. Following removal of acetone
by evaporation, solutions were concentrated to a final
volume of 2.5 mL. Finally, the NPs were washed twice
with PBS by using Amicon 10 kDa filters (MilliPore,
Czech Republic), and the PTX concentration was mea-
sured using HPLC as described earlier29 and adjusted to
15 mg⋅mL−1.
The NR-loaded P1 and P2 NPs were prepared as fol-
lows: 5 mL solutions containing 20 mg P1 or P2 and 50 µg
NR in acetone, PBS (containing 0.01% (v/v) Tween 80)
were added (10 mL) as a precipitant. Acetone was then
removed by evaporation and the volume was adjusted to
give a concentration of the NPs of 5 mg⋅mL−1. The NPs
were washed twice with PBS by using Amicon 10 kDa
filters (MilliPore). The final preparations were adjusted
such that they contained 8.0 µg⋅mL−1 of NR in PBS with
0.2% (w/v) of the polymers.29
NP characterization
Dynamic light scattering measurements were performed by
using the Zetasizer NanoZS, Model ZEN3600 (Malvern
Instruments, Malvern, UK). The Zetasizer was equipped
with a 633 nm He-Ne laser and it was operating at an
angle of 173°. The Dispersion Technology Software version
6.01 fromMalvern was used to collect and analyze the data.
One mL of the NPs was measured in disposable polystyrene
half-micro cuvettes of 10 mm at 25°C or 37°C. The mea-
surements were performed at a position of 4.65 mm from
the cuvette wall (using an automatic attenuator). Each mea-
surement of the NP dispersion lasted for 45 s and was
repeated ten times. The instrument software was used to
calculate the average hydrodynamic diameter DH and the
width of the distribution denoted as the polydispersity index
PDI. Additionally, the zeta-potential, describing the surface
charge of the NPs, is obtained from the measured data.
Size exclusion chromatography (SEC) of
the polymer NPs
SEC analysis was used to estimate the weight-average
molecular weight (Mw), number-average molecular weight
(Mn) and the respective polydispersity I = (Mw/Mn).
29 These
analyses were performed at 25°C. The columns used were
two PLgel MIXED-C columns (300×7.5 mm, styrene-divi-
nylbenzene copolymer (SDV) gel with particle size 5 μm.
The linearMw operation range for this system is in the range
of 0.200–200 kDa (Polymer Laboratories, USA). UV detec-
tion was performed using UVD 305 (Watrex, Czech
Republic) and RI detection was performed using RI-101
(Shodex, Japan). The mobile phase (DMF containing LiBr
Dovepress Pandya et al
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[0.01% v/v]) was used at a flow rate of 1 mL⋅min−1. Clarity
software (DataApex, Czech Republic) was used to calculate
the molecular weight values, and calibration was performed
with PMMA standards (Polymer Source). The MWs of P1
and P2 were determined to be 21.5 kDa (I =49) and 21.9
kDa (I =1.64), respectively.29
SEC analysis of polymer degradation
Solutions of P1 and P2 NPs were made prepared by adding
6 mg of the polymers to 1.6 mL of DMF-PBS (pH 7.4, 80/
20 v/v). H2O2 (30% w/w solution in H2O) was added to
obtain solutions containing 500 µM, 1 mM and 5 mM
H2O2, respectively. After incubations for 1 or 3 days,
aliquots of 250 µL were evaporated to dryness, and 350
µL DMF (containing 0.01% (w/v) LiBr) was added. The
solutions were filtered 0.22 µM PVDF (Millipore) and 20
µL were injected for SEC analysis.
Cell culture
HeLa (cervical cancer cell line) cells, purchased from
American Type Culture Collection (ATCC), were cultured
in RPMI medium with 10% (v/v) fetal bovine serum
(Sigma-Aldrich) and 1%(v/v) GlutaMax (Life
Technologies, CA, USA). PC-3cells (a hormone-indepen-
dent prostate carcinoma cell line) were purchased from
ATCC and cultured in F12 medium with 10% (v/v) fetal
bovine serum, 100 µg/mL streptomycin and 100U penicil-
lin (Life Technology, Czech Republic). Cells were incu-
bated in a humidified incubator at 37°C with 5% (v/v)
CO2. The cell culture was split twice a week and regularly
tested for mycoplasma contamination and cell identity.
The latter was verified using the Powerplex 16 kit
(Promega, Madison, WI, USA) based on analyses of geno-
mic DNA. The HeLa cells were detached using cold
0.02% (w/v) EDTA (Sigma-Aldrich), washed and re-sus-
pended in PBS before injection in mice.
Confocal laser scanning microscopy
High ROS-producing PC-3 cells28 were seeded in 8-well µ-
slides (Ibidi GmbH, Germany) at a density of 2.104 cells per
well. Cells were left to attach overnight, before addition of
NR-loaded P1 or P2NPs (200 µg.mL−1) for 2 hrs for inter-
nalization of the NPs into the cells. After removal of the non-
internalized NPs, the cells were further incubated for 4 and 20
hrs before the cells were washed and kept in PBS containing
0.5% (w/v) bovine serum albumin. The nuclei were stained
with 1 µg.mL−1 of Hoechst 34,580 (all Life Technologies,
Czech Republic) prior to imaging. Images were acquired at
an Olympus FV 10-ASV confocal laser scanning microscope
with a 60X oil objective, using the software FluoView
FV1000. Transmission and Hoechst fluorescence (channel
CH1, excitation 405 nm, emission 425–475 nm) were
detected. The NR fluorescence was imaged in channels CH2
(excitation 543 nm, emission 555–625 nm) and CH3 (excita-
tion 635 nm, emission 655–755 nm).
Flow cytometry
For particle chase experiments, PC-3 cells were seeded as
given above, then the cells were chased with NR-loaded
P1 or P2 NPs (200 µg.mL−1 for 2 h). Then, NR fluores-
cence in the cells was measured immediately (0 hr post-
chase) or after 4 hrs additional incubation in NP-free
medium (4 hrs post-chase). The cells were trypsinized
and washed with PBS containing 0.5% (w/v) BSA and
proceeded for flow cytometry analysis.
For the catalase experiments, the PC-3 cells were seeded
at a density of 5.104 cells per well and left to attach over-
night. Afterward, cells were incubated with 2000 U⋅mL−1 of
catalase for 16 hrs before addition of P1 and P2 NR-loaded
NPs (200 μg⋅mL−1). The NPs were incubated with the cells
for further 6.5 hrs before proceeded for flow cytometry
analysis. NR-loaded P1 and P2 NPs (200 μg⋅mL−1) were
also incubated with cells without addition of catalase and
were used as controls.
Measurements and data analyses were done with a
FACSverse flow cytometer (BD Biosciences, USA) using
the FlowJo V10 (FlowJo, USA) and OriginLab software
(OriginLab Corporation, USA). Single cells were selected
in plots of forward scatter area (FSC-A) vs sideward
scatter area (SSC-A) (for exclusion of debris) and FSC-A
vs FSC height (for duplet discrimination).
The green part of the fluorescence of particle-incorpo-
rated NR (FL1, excitation 488 nm, emission BP527/32, ie,
bandpass filter at 527±16 nm) and the red-shifted
quenched fluorescence of NR released from degraded par-
ticles (FL5, excitation 640 nm, emission BP660/10, ie,
bandpass filter at 660±5 nm) were captured. The ratio of
the two fluorescence intensities (‘FL5/FL1ʹ) was a mea-
sure for the release of NR, ie, to estimate NP degradation.
Experimental animals
Female athymic nude foxn1nu mice were bred at the
Comparative Medicine Department, Oslo University
Hospital, and kept in a specific pathogen-free environment at
a constant temperature (21.5±0.5°C) and humidity (55±5%);
15 air changes/h and a 12-hr light/dark cycle. The animals
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were 5–6 weeks old and their weight was 18–20 g before they
were included in the experiments. Anesthesia was obtained
with 5% (v/v) Sevofluran along with 1 L oxygen and 3 L
nitrous oxide, given with inhalation mask. Mice were given
cardboard houses and paper to play with. All the experiments
were approved by the National Animal Research Authority,
after first having been approved by the institutional veterinar-
ian. Housing and all procedures involving animals were per-
formed according to protocols approved by the National
Animal Research Authority, and conducted according to the
regulations of the Federation of European Laboratory Animals
Science Association.32 Food and water were supplied ad libi-
tum. Animals were sacrificed performing cervical dislocation
at the end of the experiments, or when tumor volume reached
1500 mm3, the weight loss exceeded 20% or when they
became moribund.
Toxicity studies
Toxicity of the PTX-loaded P1 and P2 NPs or nab-PTX
was examined by injecting different doses (10, 20, 40 or
60 mg/kg body weight) in disease-free female athymic
nude foxn1nu mice. The animals were monitored daily
the first week and thereafter twice per week for weight
loss or any sign of toxicity. Weight loss should not exceed
20%. There were six animals per treatment group.
In vivo imaging
P1 or P2 NPs conjugated with the fluorescent dye
AlexaFluor 647 were used to study biodistribution in
healthy mice using an in vivo imaging system IVIS®
Spectrum (Perkin Elmer, MA, USA). Mice were injected
intravenously with NPs containing 270 µg AlexaFluor
647conjugated with 11.3 mg NPs in 250 µL. The mice
were given the abovementioned gas anesthesia using mul-
tiple masks. The excitation/emission wavelength pair of
640/680 nm was used for imaging of the NPs. Full body
images were obtained 1, 4 and 24 hrs after injection; the
animals then were sacrificed and organs were harvested.
Ex vivo imaging of the organs was also performed with
the IVIS® Spectrum using the same settings as above.
Relative signal intensity in the organs, such as liver,
lungs and spleen was calculated, using Living Image soft-
ware (Perkin Elmer), as radiant efficiency (Emission light
[photons/sec/cm2/str]/Excitation light [μW/cm2]×109) per
pixel of the region of interest, which was marked around
the corresponding organs. Organs from only one animal
from different treatment at each time point were imaged.
Treatment efficacy
The anti-tumor treatment efficacy was investigated in
HeLa tumor-bearing mice, for which, 2.5 million HeLa
cells were injected subcutaneously on each flank of mice
to develop bilateral tumors. After the tumors reached
approximately 5 mm in diameter, the mice were randomly
allocated to the following treatment groups: P1 NPs, P2
NPs, nab-PTX, PTX and saline.
Free PTX solution was made right before the injection
by dilution of the working solution with 0.9% (w/v) NaCl.
All treatments were given as intravenous injections and the
mice were monitored daily. The tumor was measured by
caliper and the tumor volume was calculated according to
the formula 0.5×length×width2 and related to the mean
tumor volume at the day when the treatment started.
Mice were sacrificed by cervical dislocation if tumor
reached 1500 mm3 or when they became moribund.
Immunohistochemistry
Tumors from HeLa-bearing mice were collected 30 days after
treatment, formalin-fixed and paraffin-embedded (FFPE).
FFPE tumors were sliced to prepare 3 µm thick consecutive
slides. The deparaffinization agentNeo-clear and themounting
agent Neo-mount were both obtained fromVWR (Radnor, PA,
USA). Heat-induced epitope retrieval was performed by pla-
cing deparaffinized slides in 10 mM sodium citrate buffer (pH
6.0) in a boiling water bath for 20 mins at 95–100°C.
Endogenous peroxidase activity was blocked by incubating
slides with 3% (v/v) hydrogen peroxide in tris-buffered saline
(TBS; 50 mM Tris-Cl, 150 mM NaCl, pH 7.6). Sections were
blocked for non-specific binding with 3% (w/v) bovine serum
albumin (Roche Diagnostics GmbH, Mannheim, Germany) in
TBS for 30–35 mins. Incubation with primary antibody was
performed for 60 mins at room temperature. MACH 3 rabbit
HRP-polymer detection kit (Biocare Medical, Concord, CA,
USA) was used for detection of primary antibodies.
Chromogen solution provided with the Betazoid DAB
Chromogen kit (Betazoid DAB Chromogen kit; Biocare
Medical) was used to develop signals. Hematoxylin and 37
mM ammonium hydroxide containing solutions (Sigma-
Aldrich, St. Louis, MO, USA) were used for counter staining.
Three different primary antibodies, ie, anti-CD68 (1
mg/mL; ab125212, Abcam, Cambridge, UK), anti-CD206
(0.1 µg/mL; ab64693, Abcam, Cambridge, UK) and anti-
iNOS (0.5 µg/mL; ab15323, Abcam, Cambridge, UK)
were used to detect diverse macrophage populations.
CD68 is generally used for detection of the whole
Dovepress Pandya et al
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macrophage population.33,34 To detect pro-inflammatory
M1 macrophages, inducible nitric oxide synthase (iNOS)
is used as a marker.35 CD206 is considered as a marker for
pro-tumorigenic M2 macrophages.35 NK cells were
detected using Anti-NCR1 (ab214468, Abcam). Negative
controls were those tissues, which were stained without
primary antibodies.
ImageJ analysis
Stained tissue sections were scanned (NanoZoomer HT,
Hamamatsu Photonics, Hamamatsu, Japan) using a 40x
objective. The digitalized slides were used to make small
frames throughout the tissue section (five frames from
each section) for better analysis and effective quantifica-
tion of CD68, iNOS, CD206 or NCR1 expressing cells.
These frames of tumor sections were transferred to ImageJ
software (NIH, USA). Annotations in each frame were
created to avoid blood vessels and necrotic parts of
tumor, as they may give false positive or background
signals. Black threshold was created to color all the
brown stained spots into black. Then, binary images
were created where only black spots were visible on
white background for efficient quantification. The pixel
numbers of black spots were calculated automatically
and divided with total pixels in white background (illu-
strated an example in Figure S2A). The obtained ratio was
used as a semi-quantitative measurement of antigen
expression in each stained section (Figure S2B).
Statistics
To calculate the significance in the efficacy studies, the
area under the curve (AUC) was calculated for each
tumor and the AUC values were compared between
groups using unpaired, two-sided t-test. Statistical analy-
sis of flow cytometry data was performed using one-way
ANOVA and Tukey’s multiple comparisons post-hoc test.
For all other studies, an unpaired two-sided Student t-test
was used. The statistical analyses were performed using
either GraphPad Prism (version 7.00 for Windows,
GraphPad Software, La Jolla, California, USA) or
Microsoft Excel 2010.
Results
In vitro polymer NPs degradation
The size distributions of the different polymers used in
different studies are shown in Figure 2(A-C) and the
values for DH, PDI and zeta-potential for all preparations
are listed in Table 1. TEM micrographs of these particles
have been published previously.29
In order to analyze the stability of the NPs in the pre-
sence of ROS, the particles were incubated in solutions
containing different H2O2 concentrations and analyzed by
SEC. The chromatograms depicted in Figure 2(D-E) reveal
that the P1 NPs degraded to smaller molecules in an H2O2-
dependent manner. The polymer degradation proceeded
more extensively at higher H2O2 concentrations. P1 NPs
were shown to be affected by physiologically relevant
levels of H2O2 (500 μM) after 1 day (Figure 2D), while
the non-ROS-sensitive counterpart P2 NPs showed almost
no degradation after 3 days incubation with the same H2O2
concentration (Figure 2E). When degradation of the two
NPs was compared at the highest H2O2 concentration tested
(5 mM), the degradation of the P2 NPs was only partial after
3 days (Figure 2E) whereas the P1 NPs were almost com-
pletely degraded after 24 hrs (Figure 2D). No degradation of
the NPs was observed following incubation for 5 days in the
absence of H2O2 (data not shown). Degradation of the NPs,
assessed by 1H NMR at the same time intervals and condi-
tions, has also been reported previously.29
Degradation of the NPs was also assessed by flow
cytometry using NPs containing the fluorescent dye NR.
While NR is highly fluorescent when incorporated inside
the NPs, ROS- dependent release of NR will result in
reduced and overall red-shifted fluorescence (quenching
and spectra shift due to polarity changes in the surround-
ing of the dye). Thus, the release of NR can be tracked
both by quenching of the overall fluorescence intensity and
by increase of the red-shifted component of the dye’s
fluorescence. Figure 3A depicts the NR quenching (shift
in the light vs dark curves) in PC-3 cells loaded with P1
NPs (Figure 3A, top), while almost no quenching is
observed in cells loaded with the P2 NPs (Figure 3A,
bottom). The NR fluorescence in cells loaded with P1
NPs is decreased by ~62% during 4 hrs, whereas only
~33% of the NR fluorescence is decreased after loading
with P2 NPs (Figure 3B).
Confocal images show that at 4 hrs post-chasing,P1 NPs
(Figure 3C) display lower fluorescence intensity in the cells
as compared to P2 NPs (Figure 3D), whereas after 20 hrs,
the fluorescence of P1 NPs (Figure 3E) is totally vanished
compared to P2 NPs (Figure 3F). Furthermore, the NR
release from the P1 and P2 NPs in PC-3 cells was also
evaluated in the presence of catalase (a ROS scavenger,
which degrades H2O2) (Figure S3A). In the absence of
catalase, the NRwas released to a high extent in cells loaded
Pandya et al Dovepress
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Figure 2 Size distribution of NPs and degradation of NPs in the presence of H2O2. The size distributions (hydrodynamic diameter, intensity weighted) for empty or
AlexaFluor polymers conjugated P1 NPs (A), empty or AlexaFluor conjugated polymers P2 NPs (B) and PTX encapsulated P1 and P2 NPs (C) are shown. The average values
of the hydrodynamic diameter (DH) and the polydispersity index (PDI) are also indicated. The SD values obtained (n=10) were smaller than the symbols used in the figure
and therefore not visible. SEC chromatograms of P1 NPs (D) and P2 NPs (E) prior to the addition of H2O2 (black lines) and after degradation for 1 day (D) and 3 days (E) in
20% PBS/DMF solutions at 37°C containing 500 (red lines), 1 (green line) or 5 mM (blue lines) H2O2.
Dovepress Pandya et al
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with the degradable P1 NPs, while the presence of catalase
prevented particle degradation and strongly reduced the NR
release (Figure S3B), demonstrating the specificity of the
P1 NPs to release the drug in the presence of H2O2. In the
case of P2 NPs, the NR release remained unchanged and
low, disregarded the presence of catalase (Figure S3C).
Toxicity studies using P1 and P2 NPs
Toxicity experiments on healthy mice were performed to
determine non-toxic dose of the different substances that
could be injected for further studies. The weights of mice
were regularly monitored to observe substance toxicity, and a
given dose was considered toxic and mice would be sacri-
ficed if weight reduction exceeded 20% compared to their
initial respective weights. Our study showed that healthy
mice could be administered a dose of 60 mg/kg PTX incor-
porated in both P1 and P2 NPs, as well as 60 mg/kg nab-PTX
without giving any sign of toxicity (Figure S4). This is in
contrast to free PTX, where maximum tolerated dose had
been reported to be 30 mg/kg body weight.36
PTX-loaded P1 NPs exhibit significant
anti-tumor efficacy
To determine anti-tumor efficacy in HeLa xenografts,
tumor-bearing animals were treated with PTX contain-
ing P1 NPs (PTX 60 mg/kg), PTX containing P2 NPs
(PTX 60 mg/kg), free PTX (15 mg/kg, two times with
six days between the injections), nab-PTX (60 mg/kg)
and PBS as control. Compared to control mice, anti-
tumor efficacy was observed after treatment with P1 and
P2 NPs, as well as after treatment with nab-PTX and
free PTX (Figure 4A). The P2 treatment group had to be
discontinued 18 days posttreatment due to some large
tumors. Although nab-PTX (60 mg/kg) treatment dis-
played improved tumor inhibition compared to control
and P2 NPs, the efficacy was not better than free PTX.
Notably, the highest anti-tumor efficacy was achieved
with the ROS-sensitive P1 NPs. When comparing all
treatment groups, the P1 NPs demonstrated significantly
improved growth retardation compared to P2 NPs and
nab-PTX, but did not reach statistical significance in
comparison with free PTX at day 18 (when the P2
group had to be discontinued). However, AUC calcula-
tions at the end of the experiment (Figure 4B) demon-
strated significant improved treatment efficacy by P1
NPs also when compared to free PTX (Figure 4A),
P=0.017 (P1 NPs – PTX), P=0.001 (P1NPs – nab-
PTX); unpaired, two-sided t-test. Also, total remission
was obtained in 5 of 11 tumors treated with P1 NPs, 1
of 10 tumors treated with nab-PTX and 2 of 10 tumors
treated with PTX.
Tissue localization of NPs
The biodistribution of the P1 or P2 NPs in healthy mice was
studied by fluorescence imaging up to 24 hrs after injection
of the NPs containing the fluorescent dye AlexaFluor 647.
The images of mice were captured using the IVIS Spectrum
scanner after 1, 4 and 24 hrs (Figure 5A), and demonstrate
that the fluorescence signals decrease faster for P2 NPs than
for P1 NPs. The mice were sacrificed to harvest organs for ex
vivo visualization. The images of all organs harvested 24 hrs
after injections are shown in Figure 5B and demonstrate
stronger signals in liver, lungs and spleen after injection of
P1 NPs than for P2 NPs. The mean radiant efficiency relative
to the pixel size of the region of interest per organ is plotted
(Figure 5C).
M1 macrophages are abundant in treated
tumors
Immunohistochemistry was performed to detect differ-
ent subsets of macrophages in treated or non-treated
tumors. Image analysis and quantification were per-
formed using the ImageJ software. Total population
of infiltrating macrophages was quantified using an
antibody against CD68. A significantly higher level of
total macrophages was observed in tumors treated with
the P1 NPs, compared to PBS (P=0.01), P2 (P=0.03),
Table 1 The average values of hydrodynamic diameter (DH),
polydispersity index (PDI) and zeta-potential (ζ) of empty,
AlexaFluor 647 (AF647) conjugated, NR-loaded, and PTX encap-
sulated polymers P1 and P2 NPs are listed
NPs DH (nm) PDI ς-potential
(mV)
Application
P1 Empty 72 0.18 – 12 Biodistribution
P1 AF647 67 0.20 – 8.6 Biodistribution
P1 NR 86 0.17 – 15 Microscopy, FC
P1 PTX 62 0.16 – 11 Toxicity, efficacy
P2 Empty 92 0.18 – 9.5 Biodistribution
P2 AF647 104 0.18 – 7 Biodistribution
P2 NR 90 0.15 – 12 Microscopy, FC
P2 PTX 94 0.20 – 13 Toxicity, efficacy
Abbreviation: FC, flow cytometry.
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nab-PTX (P=0.04) or PTX (P=0.04) (Figure 6A). Also,
the marker of pro-inflammatory/anti-tumorigenic M1
macrophages (iNOS) showed significantly higher
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Figure 3 Flow cytometry and confocal microscopy images. Histograms show NR total fluorescence after 0 hr post-chasing (light blue/light green) and NR quenching in PC-3
cells 4 hrs post-chasing (dark blue/dark green) with P1 NPs (A; top panel) and P2 NPs (A; bottom panel). Grey curves indicate cells without fluorescence. Mean total NR
fluorescence in PC-3 cells after 2 hrs chase with NR-loaded NPs 0 and 4 hrs post-chase (B). Confocal images of PC-3 cells after incubation with NR-loaded P1 NPs (left
panel) and P2 NPs (right panel) for 4 (C, D) or 20 hrs (E, F) post-chasing. Error bars show SD. Asterisk indicates statistical significance obtained by one-way ANOVA and
Tukey’s multiple comparisons post-hoc test. *P<0.05 (n=3).
Dovepress Pandya et al







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
P1 NPs compared to PBS (P=0.02), P2 (P=0.02), nab-
PTX (P=0.03) or PTX (P=0.03) (Figure 6B). However,
the CD206 positive cells, representing the anti-inflam-



























































Figure 4 Treatment efficacy in mice bearing HeLa tumors. (A) The effect of the different treatments on HeLa tumors in mice was studied for 30 days. PTX containing P1 NPs, P2
NPs or nab-PTXwere injected with 60mg/kg PTX. Free PTXwas injected twice (day 1 and 7); 15mg/kg in each injection. The blue arrows indicate PTX injections. PBS was used as a
control. Data are shown as mean±SEM (P1NPs: n=11; P2 NPs, nab-PTX and PTX: n=10). Statistical significance between the treatment groups was calculated using AUC of
individual tumors. Error bars show SEM. Asterisks indicate statistical significance obtained by two-tailed unpaired t-test. *P<0.05, **P<0.005. (B) Relative tumor volume at day 18
after the treatment plotted before two treatment groups were discontinued due to very large tumors. Statistical significancewas determined using two-tailed unpaired t-test. Error
















































Figure 5 Biodistribution of P1 or P2 in healthy mice. In vivo fluorescence imaging of healthy mice at 1, 4 and 24 hrs after i.v. administration of unconjugated or AlexaFluor
647 (AF647) conjugated P1 or P2 NPs (A). Ex vivo fluorescence images of isolated organs, 24 hrs after injection (B). The columns demonstrate total radiant efficiency per
pixel of region of interest of liver, lungs and spleen after 24 hrs (C). *SI=small intestine.
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infiltration after injection of P1 NPs than in tumors
receiving PBS (P=0.006),and somewhat less, although
not statistically significant, than P2 NPs (P=0.1)
(Figure 6C). Selected photomicrographs of stained sec-
tions are presented for visualization (Figure S5A-E).
Only a few NCR1 expressing NK cells were detected
in the tumors and no significant difference (P=0.09)
was observed between the groups treated with P1 NPs
or P2 NPs (Figure S6).
Discussion
ROS are known to be elevated during inflammation and in
tumors.3,37 Here, we used NPs designed to become degraded
and release drug cargo, in this case PTX, in a ROS-enriched
microenvironment.29 We showed an effective degradation of
ROS-sensitive P1 polymers in the presence of ROS using
SEC analysis, confocal laser microscopy as well as flow
cytometry with high ROS-producing PC-3 cells. Using
HeLa xenografts in mice, we demonstrated superior anti-
tumor efficiency of PTX embedded in ROS-sensitive NPs
compared to PTX embedded in ROS-non-sensitive NPs, free
PTX and nab-PTX, ie, a commercial product containing PTX
bound to albumin. We did not observe any measurable toxi-
city following injection of PTX in the ROS-sensitive NPs.
Previously it has been established that biocompatible
and biodegradable ROS-sensitive polymers containing
boronic ester groups self-degrade in ROS-rich areas and
thereby release their drug cargo.29 Recently, superior
activity of PTX-loaded pH-sensitive acetal-PEGylated
NPs compared to free PTX has been demonstrated against
HeLa cells in vitro.38 Similarly, Lu et al showed a better
antitumor efficacy of PEGylated PTX than free PTX.39 In
line with these findings, our data demonstrate less toxicity
and better anti-tumor efficacy when PTX was incorporated
into the ROS-sensitive NPs. There are at least two possible
explanations for the improved therapeutic effect of treat-
ment with P1 NPs compared to free PTX. Firstly, it was
possible to deliver as high as 60 mg/kg PTX without
demonstrating toxicity on healthy animals in formulation
with P1 NPs, while the maximum tolerated dose of free
PTX is only 30 mg/kg. Consequently, these NPs may
deliver higher amounts of PTX in the tumor, limit the
systemic exposure, and thus reduce toxicity and improve
the selectivity of the treatment. However, the free PTX
concentration in tumor was not quantified, hence we do
not know if all PTX delivered by using NPs are available
for their target inside tumors. Also, the better efficacy of
the ROS-sensitive NPs compared to free PTX was
observed many days after injection of these substances,
and one may speculate if the better efficacy following
injection of the NPs may be to ROS-triggered drug release
over time.
The size of NPs is an important factor to achieve efficient
tumor accumulation caused by the enhanced permeability
and retention effect.40 Our ROS-non-sensitive P2 NPs used
in the mice studies have approx. 30 nm larger hydrodynamic
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Figure 6 Expression of macrophage markers in untreated or treated HeLa tumor
tissues. Macrophage infiltration was measured in HeLa tumors after treatment with
PBS, P1 NPs, P2 NPs, nab-PTX or PTX. The total population of infiltrated macro-
phages was quantified using an antibody to CD68 (A). The population of pro-
inflammatory (anti-tumorigenic) M1 macrophages was quantified using an antibody
to iNOS (B). The population of anti-inflammatory (pro-tumorigenic) M2 macro-
phages was quantified with an antibody to CD206 (C). Data are shown as mean-
stained pixel ratio±SEM (n=5 random regions in each tumor). Calculation of the
stained pixel ratio is illustrated in Figure S2. Asterisks indicate statistical significance
obtained by two-tailed unpaired t-test. *P<0.05, **P<0.006.
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biodistribution of these NPs obtained 24 hrs after intravenous
injection in mice is shown in Figure 5. It is not obvious why
there seems to be more fluorescence accumulating in liver,
spleen and lungs following injection of ROS-sensitive than
ROS-non-sensitive NPs. A size difference between P1 and
P2 NPs might contribute to different accumulation in these
organs, but in this case, a higher accumulation of the larger
P2 NPs could be expected. However, we have previously
shown that incubations of P1 NPs with 1mMH2O2 for 24 hrs
at 37°C resulted in the appearance of both some very small,
degraded particles (11 nm) and some very large aggregates
(1.9 µm), whereas no changes were observed in the size
distribution of P2 NPs at these conditions.29 Thus, we spec-
ulate if the ROS-sensitive P1 NPs by passing tissue with
elevated ROS levels may undergo swelling/aggregation and
therefore get trapped. Interesting in this connection is that
lungs are continuously exposed to oxygen and exogenous
oxidants, such as dust particles or endogenous oxidants pro-
duced by macrophages, alveolar, bronchial and endothelial
cells.41 Also, spleen homes abundant amounts of ROS-pro-
ducing myeloid-derived suppressor cells,42 which might
explain the profound number of ROS-sensitive P1 compared
to P2 NPs in this organ.
Furthermore, the differences observed in the IVIS bio-
distribution data may also be due to different release rates
of fluorophore from the two NPs such that the differences
observed cannot be directly correlated to the amount of
NPs in these tissues. We demonstrated in the present study
a more rapid particle degradation and release from P1 than
from P2 NPs during incubation in the presence of H2O2
(Figure 2D-E). In ROS-producing PC-3 cells, we observed
approximately twice as much NR in P2 NPs as in P1 NPs
after 4 hrs of incubation (Figure 3). Furthermore, the NR
release from P1 NPs was shown to be inhibited in the
presence of ROS-scavenger agent (catalase), demonstrat-
ing the specificity of the P1 NPs to release the cargo in the
presence of H2O2.
We have, as discussed above, shown that the ROS-
sensitive NPs are activated in vitro. However, there are
several challenges in comparing in vitro and in vivo ROS
levels,43,44 and both artificially high levels of metabolic
substrates and high partial pressures of oxygen45 make it
difficult to extrapolate in vitro results to the in vivo
situation.43,46 Moreover, exact measurement of the ROS
levels in intact organs and tumors are technically challen-
ging due to their very short life span, high activity and
extremely low concentration.47 In any case, the data
obtained clearly demonstrate that the P1 NPs are much
more active than the P2 NPs in the subcutaneously grow-
ing tumors in vivo, resulting in a more pronounced ther-
apeutic effect.
We also investigated the importance of the innate
immune responses and related this to the observed treat-
ment efficacy. Although NK cells are essential as a first
line of defense against metastasis from circulating tumor
cells, they are mostly not associated with the defense
against tumor cells located in the tissues. Hence, the
densities of NK cells found in tumors in most animal
tumor models are low,48 in accordance with the data in
the present study. Contrary to NK cells, macrophages are
the most abundant immune cells in the tumor microenvir-
onment, and TAMs can be involved in both pro- and anti-
tumorigenic processes. The TAM population is highly
diverse with interchangeable phenotypes.49 Macrophages
have been subdivided into the classically activated pro-
inflammatory M1 type, which exhibits anti-tumor
immune response and the alternatively activated M2
type, which plays a more pro-tumorigenic role by secret-
ing anti-inflammatory cytokines.50,51 Involvement of
TAMs in tumor-related inflammation and induction of
ROS also occurs through their production of cytokines,
such as interferon-γ, interleukin-6 and tumor necrosis
factor-α.37,52,53 However, the functional role of TAMs
varies between different forms of cancers, where they
may contribute to either a favorable or poor prognosis.54
Our immunohistochemistry results showed elevated
expression of the M1 (anti-tumorigenic) specific marker
in the tumors treated with P1 NPs, ie, in the tumors where
the best therapeutic effect was observed. Treatment with
ROS-sensitive NPs containing PTX displayed elevated
CD68 and M1 macrophage-specific iNOS expression.
This may suggest an ability of P1 NPs to induce anti-
tumoral inflammation. Interestingly, tumor growth inhibi-
tion induced by docetaxel (another taxane) has been shown
to partly depend upon expansion of M1 macrophages and
depletion of M2 macrophages in models of breast cancer.55
In contrast, enrichment of M1 macrophages was similarly
observed after treatment of mice with cabazitaxel-loaded
poly (2-ethylbutyl) cyanoacrylate NPs but not with free
cabazitaxel.56 Similarly, we did not observe any response
in the macrophage populations upon treatment with free
PTX, despite significant tumor inhibition compared to
untreated controls.
Recently, PTX has been shown to reduce tumor
growth by reprogramming TAMs to an M1 profile.57
This might explain increased infiltration of M1
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macrophages in PTX containing P1 treated tumors.
Another interesting aspect of our finding is significantly
decreased expression of pro-tumoral M2 macrophage
marker CD206 upon P1 NPs treatment compared to con-
trol (P=0.006) group. This might point toward a possible
role of M2 macrophages as a marker for poor prognosis
concerning this treatment. Although only a small number
(n=5) of immunohistochemical analyses were performed,
the data point toward involvement of the innate immune
system as a possible mechanism contributing to the
enhanced treatment efficacy observed upon PTX delivery
by ROS-sensitive NPs.
Conclusion
Injection of ROS-sensitive NPs containing PTX gave an
improved therapeutic effect in HeLa xenografts in mice
than injection of similar NPs containing a ROS-non-sensi-
tive counterpart, free PTX or nab-PTX containing albu-
min-bound PTX. Our data revealed a correlation between
macrophage infiltration and efficiency of the different anti-
tumor treatments, as the most effective NPs resulted in the
highest infiltration of the anti-tumorigenic M1
macrophages.
Abbreviation list
AUC, area under the curve; DLS, dynamic light scattering;
DMF, N,N-dimethylformamide; EPR, enhanced permeability
and retention; FFPE, formalin-fixed and paraffin-embedded;
Inos, inducible nitric oxide synthase; i.v., intravenously; nab-
PTX, Abraxane®; NK, natural killer; NPs, nanoparticles; PDI,
polydispersity index; PTX, paclitaxel; SEM, standard error of
the mean; TAMs, tumor-associated macrophages; TBS, tris-
buffered saline.
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Figure S1 Structure of polymers. Polymers synthesized and utilized for the preparation of the PTX-loaded P1 NPs (A) and P2 NPs (B). (C) AlexaFluor 647 conjugated NPs
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Figure S2 Calculation of myeloid cell infiltration in tumor tissue. The displayed photomicrograph slide was digitalized and randomly selected frames were imported to
ImageJ software. Subsequently, black threshold was created over original frame and a binary mask was created to visualize black spots on white background (A).
Quantification of shown example displays stained pixelated area, total pixelated area, pixel size and pixel count. The ratio of the stained area pixel to the total area pixel
is called the stained pixel ratio and is shown on the y-axes in Figures 6 and S6 (B).
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Figure S3 Flow cytometry and confocal microscopy images in the presence of catalase. NR fluorescence ratio of released NR (red channel – FL5) vs entrapped NR (green
channel – FL1) from P1 NPs (blue) and P2 NPs (green) without catalase or after the 16-hr pretreatment with catalase (A). Confocal images of NR-loaded P1 NPs (B) and P2
NPs (C) in PC-3 cells after a 16hr pretreatment with catalase. Red shows the fluorescence from released and quenched NR and green shows the fluorescence from the
particle-trapped, non-quenched NR; the blue color shows the Hoechst-stained nucleus. Error bars show SD. Asterisks indicate statistical significance obtained by one-way
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Figure S4 Toxicity of P1 NPs, P2 NPs and nab-PTX in healthy mice. Weight change (%) in healthy mice after treating with 40 or 60 mg/kg PTX containing P1 NPs, P2 NPs or
nab-PTX. Error bars show SEM.
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Figure S5 Photomicrographs of HeLa tissue samples labeled with CD68, iNOS or CD206. Photomicrographs of untreated tissue (A), and following treatment with P1 NPs

















Figure S6 Expression of the NK cell marker NCR1 quantified in P1 NPs and P2 NPs treated tumors. Calculation of the stained pixel ratio was performed as illustrated in
Figure S2. Data are shown as mean-stained pixel ratio±SEM (n=5 random regions in each tumor). The difference was not statistically significant.
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